Bioasis Technologies Inc (OTCQB:BIOAF) (TSX.V:BTI) CEO Dr. Deborah Rathjen tells Proactive the pre-clinical biopharma group has received positive feedback from the FDA on its pre-investigational new drug (IND) application for its xB3-001 therapy for the treatment of patients with a type of breast cancer and brain metastases. Rathjen says the FDA's favorable feedback included a suggestion the company might consider the next steps of the drug development process towards entering Phase 1 trials.
Full interview: Bioasis Technologies new CEO says favorable response from FDA on its xB3 therapy 'encouraging'
Quick facts: Bioasis Technologies Inc.
Price: 0.2819 USD
Market Cap: $19.13 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE